COMP <GO>
TRLV vs JNJ // EV/EBITDA & P/E VALUATION
Trulieve Cannabis Corp. Subordinate Voting Shares (NYSE) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: TRLV 2
— JNJ 9
▲ EV/EBITDA & P/E VALUATION LEADER: TRLV
LAST: $10.60 (-0.19%) • MKT CAP: $2.04B
valuation
9.9x
LAST: $275.20 (+1.54%) • MKT CAP: $662.49B
valuation
18.5x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (TRLV VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | TRLV | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 60.20% | 67.90% | -7.70 | JNJ | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 12.80% | 25.50% | -12.70 | JNJ | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 9.9x | 18.5x | -8.60 | TRLV | /valuation <GO> |
| Free Cash Flow Yield | 11.20% | 2.97% | +8.23 | TRLV | /fcf-yield <GO> |
| Operating Margin | 12.10% | 34.70% | -22.60 | JNJ | /operating-margins <GO> |
| Net Profit Margin | -9.90% | 28.50% | -38.40 | JNJ | /net-margins <GO> |
| Revenue Growth (YoY) | -0.40% | 6.00% | -6.40 | JNJ | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 1.12 | 5.59 | -4.47 | JNJ | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 8/9 | -2.00 | JNJ | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 43.3 | 62.1 | -18.83 | JNJ | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.08 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 23.0x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $2.04B | $662.49B | -$660.45B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | TRLV REV | JNJ REV | TRLV GROSS % | JNJ GROSS % | TRLV FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $1.18B | $94.19B | 60.2% | 67.9% | $228.6M | $19.70B |
| FY 2024 | $1.19B | $88.82B | 60.3% | 69.1% | $148.9M | $19.84B |
| FY 2023 | $1.13B | $85.16B | — | — | $201.8M | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
TRLV // BETA —
JNJ // BETA 1.08